With $220 million in facility-specific investment, this project clears AFT's $100 million investment threshold (AFT includes any project meeting $100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Lonza
- Industry
- Pharmaceuticals
- Location
- Portsmouth, New Hampshire
- Investment
- $220.0M
- Permanent jobs announced
- 0
- Status
- Operational
- Announced
- May 6, 2021
- Operations began
- 2024
- Added to tracker
- Aug 14, 2026
Official references
- Original company announcement https://www.lonza.com/news/2021-05-06-07-02
- 2024 operational ramp-up evidence https://www.lonza.com/annualreport/2024/our-businesses/biologics
- Contemporaneous USD equivalent evidence https://www.pharmtech.com/view/lonza-to-expand-sites-with-next-generation-mammalian-manufacturing-facilities